Traditional and New Influenza Vaccines

Classifications Services CMR Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue CMR About CMR Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commerc...

Full description

Saved in:
Bibliographic Details
Published inClinical Microbiology Reviews Vol. 26; no. 3; pp. 476 - 492
Main Authors Wong, Sook-San, Webby, Richard J.
Format Journal Article
LanguageEnglish
Published Washington, DC American Society for Microbiology 01.07.2013
Subjects
Adjuvants, Immunologic
Animals
Applied microbiology
Biological and medical sciences
Birds
Fundamental and applied biological sciences. Psychology
Humans
Infectious diseases
Influenza Vaccines - administration & dosage
Influenza Vaccines - immunology
Influenza, Human - prevention & control
Medical sciences
Microbiology
Orthomyxoviridae Infections - prevention & control
Reviews
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - immunology
Infection
Vaccine
Review
Viral disease
Influenza
Online AccessGet full text

Cover

Abstract Classifications Services CMR Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue CMR About CMR Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy CMR RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0893-8512 Online ISSN: 1098-6618 Copyright © 2014 by the American Society for Microbiology.   For an alternate route to CMR .asm.org, visit: CMR       
AbstractList The challenges in successful vaccination against influenza using conventional approaches lie in their variable efficacy in different age populations, the antigenic variability of the circulating virus, and the production and manufacturing limitations to ensure safe, timely, and adequate supply of vaccine. The conventional influenza vaccine platform is based on stimulating immunity against the major neutralizing antibody target, hemagglutinin (HA), by virus attenuation or inactivation. Improvements to this conventional system have focused primarily on improving production and immunogenicity. Cell culture, reverse genetics, and baculovirus expression technology allow for safe and scalable production, while adjuvants, dose variation, and alternate routes of delivery aim to improve vaccine immunogenicity. Fundamentally different approaches that are currently under development hope to signal new generations of influenza vaccines. Such approaches target nonvariable regions of antigenic proteins, with the idea of stimulating cross-protective antibodies and thus creating a "universal" influenza vaccine. While such approaches have obvious benefits, there are many hurdles yet to clear. Here, we discuss the process and challenges of the current influenza vaccine platform as well as new approaches that are being investigated based on the same antigenic target and newer technologies based on different antigenic targets.The challenges in successful vaccination against influenza using conventional approaches lie in their variable efficacy in different age populations, the antigenic variability of the circulating virus, and the production and manufacturing limitations to ensure safe, timely, and adequate supply of vaccine. The conventional influenza vaccine platform is based on stimulating immunity against the major neutralizing antibody target, hemagglutinin (HA), by virus attenuation or inactivation. Improvements to this conventional system have focused primarily on improving production and immunogenicity. Cell culture, reverse genetics, and baculovirus expression technology allow for safe and scalable production, while adjuvants, dose variation, and alternate routes of delivery aim to improve vaccine immunogenicity. Fundamentally different approaches that are currently under development hope to signal new generations of influenza vaccines. Such approaches target nonvariable regions of antigenic proteins, with the idea of stimulating cross-protective antibodies and thus creating a "universal" influenza vaccine. While such approaches have obvious benefits, there are many hurdles yet to clear. Here, we discuss the process and challenges of the current influenza vaccine platform as well as new approaches that are being investigated based on the same antigenic target and newer technologies based on different antigenic targets.
The challenges in successful vaccination against influenza using conventional approaches lie in their variable efficacy in different age populations, the antigenic variability of the circulating virus, and the production and manufacturing limitations to ensure safe, timely, and adequate supply of vaccine. The conventional influenza vaccine platform is based on stimulating immunity against the major neutralizing antibody target, hemagglutinin (HA), by virus attenuation or inactivation. Improvements to this conventional system have focused primarily on improving production and immunogenicity. Cell culture, reverse genetics, and baculovirus expression technology allow for safe and scalable production, while adjuvants, dose variation, and alternate routes of delivery aim to improve vaccine immunogenicity. Fundamentally different approaches that are currently under development hope to signal new generations of influenza vaccines. Such approaches target nonvariable regions of antigenic proteins, with the idea of stimulating cross-protective antibodies and thus creating a “universal” influenza vaccine. While such approaches have obvious benefits, there are many hurdles yet to clear. Here, we discuss the process and challenges of the current influenza vaccine platform as well as new approaches that are being investigated based on the same antigenic target and newer technologies based on different antigenic targets.
Classifications Services CMR Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue CMR About CMR Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy CMR RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0893-8512 Online ISSN: 1098-6618 Copyright © 2014 by the American Society for Microbiology.   For an alternate route to CMR .asm.org, visit: CMR       
Author Sook-San Wong
Richard J. Webby
Author_xml – sequence: 1
  givenname: Sook-San
  surname: Wong
  fullname: Wong, Sook-San
  organization: Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
– sequence: 2
  givenname: Richard J.
  surname: Webby
  fullname: Webby, Richard J.
  organization: Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27516629$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/23824369$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1v1DAQxS1URLeFG2eUC4gDKR7bceJLJbTio1IBCa24jmadSdcocYqdpYK_nmx3y5fEaQ7zm_dG752IozhGFuIxyDMA1bxcvv90JqV0dQnqnliAdE1pLTRHYiEbp8umAnUsTnL-IiUYo5sH4ljpRhlt3UI8WyVqwxTGSH1BsS0-8E1xEbt-y_EHFZ_J-xA5PxT3O-ozPzrMU7F683q1fFdefnx7sXx1WfpKVlPZGrIE5Ixs1npdt-y80lyzZ2Os1R1baGXnXEUMa69r0r4i0MaQhrry-lSc72Wvt-uBW89xStTjdQoDpe84UsC_NzFs8Gr8hroGZ5ybBZ4fBNL4dct5wiFkz31PkcdtRtCuMUo7UDP65E-vXyZ32czA0wNA2VPfJYo-5N9cXYG1asepPefTmHPiDn2YaBfp_GLoESTuisK5KLwtCm_dX_xzdKf7H7zY45twtbkJiZHygH5IqCxqNLXVPwG-MJ2Z
CODEN CMIREX
CitedBy_id crossref_primary_10_1016_j_vaccine_2018_01_050
crossref_primary_10_1073_pnas_1805268115
crossref_primary_10_5937_arhfarm1906469B
crossref_primary_10_1007_s00705_016_2815_x
crossref_primary_10_2174_1874279301810010047
crossref_primary_10_3390_molecules27144376
crossref_primary_10_3390_v10120708
crossref_primary_10_3389_fimmu_2021_745625
crossref_primary_10_1007_s00705_017_3682_9
crossref_primary_10_3390_vaccines9070787
crossref_primary_10_3390_v16010163
crossref_primary_10_1055_a_2500_1878
crossref_primary_10_2807_1560_7917_ES_2017_22_1_30435
crossref_primary_10_1021_acs_jmedchem_6b01852
crossref_primary_10_1038_srep18062
crossref_primary_10_1016_j_semerg_2018_09_005
crossref_primary_10_1371_journal_pone_0295522
crossref_primary_10_3390_vaccines12111220
crossref_primary_10_1371_journal_pone_0101835
crossref_primary_10_1080_21645515_2015_1011987
crossref_primary_10_3390_vaccines8030546
crossref_primary_10_3390_v11020190
crossref_primary_10_1080_14760584_2022_2085565
crossref_primary_10_1021_acsnano_3c07669
crossref_primary_10_1038_srep20137
crossref_primary_10_1038_icb_2017_32
crossref_primary_10_1016_j_ijpharm_2023_123081
crossref_primary_10_1038_s41541_024_01037_1
crossref_primary_10_3390_v10100560
crossref_primary_10_1016_j_vaccine_2018_12_005
crossref_primary_10_3390_v13061109
crossref_primary_10_1371_journal_pone_0290046
crossref_primary_10_1016_j_biomaterials_2015_04_007
crossref_primary_10_3390_v14061312
crossref_primary_10_1002_cti2_1107
crossref_primary_10_1128_mbio_02161_24
crossref_primary_10_3389_fmicb_2025_1558482
crossref_primary_10_1016_j_psj_2024_104565
crossref_primary_10_1016_j_vaccine_2016_01_030
crossref_primary_10_1038_s41598_018_24764_7
crossref_primary_10_1016_j_antiviral_2016_07_019
crossref_primary_10_1128_spectrum_00445_24
crossref_primary_10_1172_JCI151732
crossref_primary_10_3390_vaccines10010112
crossref_primary_10_1016_j_virol_2017_01_020
crossref_primary_10_3390_pharmaceutics12050441
crossref_primary_10_3390_vaccines7040127
crossref_primary_10_1016_j_xcrm_2024_101433
crossref_primary_10_1371_journal_ppat_1006064
crossref_primary_10_3390_vaccines11040780
crossref_primary_10_1002_bit_27803
crossref_primary_10_1371_journal_pone_0193876
crossref_primary_10_3390_v14061323
crossref_primary_10_1016_j_vacun_2018_10_001
crossref_primary_10_1128_cmr_00103_22
crossref_primary_10_1016_j_isci_2023_106309
crossref_primary_10_1016_j_vaccine_2016_05_030
crossref_primary_10_1021_acs_biomac_4c00365
crossref_primary_10_1038_s41541_017_0017_5
crossref_primary_10_1007_s00203_022_03133_z
crossref_primary_10_5897_AJMR2016_8021
crossref_primary_10_1080_14760584_2017_1395702
crossref_primary_10_1093_cid_ciz1034
crossref_primary_10_3390_microorganisms12112294
crossref_primary_10_1016_j_vaccine_2016_08_082
crossref_primary_10_1007_s00705_015_2587_8
crossref_primary_10_1007_s00011_020_01377_3
crossref_primary_10_1002_jmv_25029
crossref_primary_10_3390_ijms23126815
crossref_primary_10_3390_v11050405
crossref_primary_10_1016_j_virol_2018_01_005
crossref_primary_10_1080_08830185_2018_1500570
crossref_primary_10_1093_infdis_jiaa255
crossref_primary_10_3390_vaccines9091032
crossref_primary_10_1016_j_semerg_2021_06_005
crossref_primary_10_3390_vaccines12050455
crossref_primary_10_24927_rce2021_032
crossref_primary_10_1016_j_vacune_2019_10_002
crossref_primary_10_1016_j_vaccine_2017_04_065
crossref_primary_10_3389_fimmu_2018_00171
crossref_primary_10_1080_14760584_2019_1582338
crossref_primary_10_1016_j_biologicals_2018_01_007
crossref_primary_10_1586_14760584_2015_1013941
crossref_primary_10_1016_j_imbio_2022_152279
crossref_primary_10_1002_biot_201400438
crossref_primary_10_1016_j_celrep_2018_08_073
crossref_primary_10_3390_vaccines8040704
crossref_primary_10_3389_fimmu_2018_00600
crossref_primary_10_1016_j_biologicals_2021_02_003
crossref_primary_10_1371_journal_ppat_1012393
crossref_primary_10_3390_molecules27051645
crossref_primary_10_1016_j_vacun_2019_07_002
crossref_primary_10_15789_2220_7619_OPO_17525
crossref_primary_10_1016_j_vaccine_2020_04_077
crossref_primary_10_3390_vaccines6020019
crossref_primary_10_1586_14760584_2016_1142878
crossref_primary_10_3390_vaccines6030058
crossref_primary_10_1080_17425255_2020_1807936
crossref_primary_10_3390_v10010002
crossref_primary_10_1016_j_sjbs_2021_05_049
crossref_primary_10_1111_cpr_12953
crossref_primary_10_1038_s41598_022_13373_0
crossref_primary_10_1016_j_omtm_2022_09_013
crossref_primary_10_1073_pnas_2004783117
crossref_primary_10_1586_14760584_2015_1039520
crossref_primary_10_1080_21645515_2024_2442104
crossref_primary_10_3390_foods11010067
crossref_primary_10_1016_j_jviromet_2017_02_015
crossref_primary_10_1016_j_pep_2024_106506
crossref_primary_10_3390_ijerph16224489
crossref_primary_10_1073_pnas_2119093119
crossref_primary_10_1016_j_nano_2015_02_008
crossref_primary_10_1021_acs_jmedchem_5b01910
crossref_primary_10_3390_vaccines11030538
crossref_primary_10_3390_vaccines7040169
crossref_primary_10_1186_s12985_019_1125_9
crossref_primary_10_1080_17460441_2017_1372417
crossref_primary_10_1146_annurev_virology_010320_044746
crossref_primary_10_1080_21645515_2020_1721223
crossref_primary_10_3389_fimmu_2024_1406929
crossref_primary_10_2217_fvl_2019_0019
crossref_primary_10_3390_ijms241310612
crossref_primary_10_1038_s41591_021_01660_8
crossref_primary_10_3390_zoonoticdis4040021
crossref_primary_10_1073_pnas_2208718120
crossref_primary_10_1016_j_vaccine_2019_10_083
crossref_primary_10_1136_bmjopen_2019_029708
crossref_primary_10_1016_j_vaccine_2015_05_053
crossref_primary_10_1080_21645515_2020_1764827
crossref_primary_10_3389_fneur_2019_00768
crossref_primary_10_1371_journal_pone_0195611
crossref_primary_10_1017_S0950268818003540
crossref_primary_10_3390_vaccines8020211
crossref_primary_10_1016_j_jvacx_2024_100552
crossref_primary_10_1088_1757_899X_778_1_012029
crossref_primary_10_3390_ijms18010020
crossref_primary_10_4049_jimmunol_1801054
crossref_primary_10_1080_14760584_2019_1639503
crossref_primary_10_3390_v10090497
crossref_primary_10_1016_j_jcis_2023_01_024
crossref_primary_10_1051_bioconf_20213700015
crossref_primary_10_1016_j_vaccine_2021_09_028
crossref_primary_10_1038_nrmicro_2017_118
crossref_primary_10_1042_CS20160259
crossref_primary_10_1093_infdis_jiab269
crossref_primary_10_1038_s41598_019_52686_5
crossref_primary_10_3389_fimmu_2023_1200718
crossref_primary_10_1208_s12249_013_0058_7
crossref_primary_10_1016_j_psj_2023_102952
crossref_primary_10_1080_14787210_2022_2144231
crossref_primary_10_1186_s12985_016_0599_y
crossref_primary_10_1038_s41598_018_28057_x
crossref_primary_10_1016_j_antiviral_2020_104782
crossref_primary_10_1016_j_lfs_2021_119744
crossref_primary_10_1089_vim_2017_0022
crossref_primary_10_1016_j_virusres_2017_09_008
crossref_primary_10_3390_vaccines11091397
crossref_primary_10_3934_medsci_2017_2_217
crossref_primary_10_1016_j_ejps_2022_106209
crossref_primary_10_1089_vim_2017_0138
crossref_primary_10_3390_vaccines12101112
crossref_primary_10_4049_jimmunol_2300026
crossref_primary_10_1016_j_drudis_2024_104125
crossref_primary_10_1128_CMR_00123_21
crossref_primary_10_1186_s43094_021_00269_5
crossref_primary_10_1016_j_vaccine_2020_07_022
crossref_primary_10_3389_fimmu_2019_01677
crossref_primary_10_1080_14760584_2023_2266033
crossref_primary_10_1111_irv_12543
crossref_primary_10_1021_acsinfecdis_6b00130
crossref_primary_10_1177_23821205231210629
crossref_primary_10_1016_j_jvacx_2024_100452
crossref_primary_10_36233_0372_9311_2019_6_30_39
crossref_primary_10_1371_journal_pone_0167952
crossref_primary_10_1016_j_vaccine_2022_12_058
crossref_primary_10_7774_cevr_2018_7_1_1
crossref_primary_10_1128_jvi_00781_24
crossref_primary_10_1016_j_vaccine_2018_10_009
crossref_primary_10_1038_s41541_024_01033_5
crossref_primary_10_3390_vaccines9010059
crossref_primary_10_1371_journal_pone_0247253
crossref_primary_10_1016_j_vaccine_2022_11_012
crossref_primary_10_1016_j_jtcme_2022_08_004
crossref_primary_10_1128_JVI_02086_14
crossref_primary_10_3390_scipharm91020028
crossref_primary_10_1586_14787210_2016_1155450
crossref_primary_10_1007_s11418_016_1028_7
crossref_primary_10_1128_JVI_00727_14
crossref_primary_10_1007_s13577_017_0168_8
crossref_primary_10_1039_D0RA09668G
crossref_primary_10_3390_vaccines6020032
crossref_primary_10_1007_s13258_021_01177_x
crossref_primary_10_1128_jvi_00896_22
crossref_primary_10_3390_vaccines8040645
crossref_primary_10_1128_JVI_02211_16
crossref_primary_10_1002_VIW_20200078
crossref_primary_10_1016_j_idc_2017_11_005
crossref_primary_10_1038_srep35033
crossref_primary_10_3390_vaccines6020031
crossref_primary_10_1039_D4NH00287C
crossref_primary_10_1128_mBio_00669_17
crossref_primary_10_3389_fimmu_2018_01479
crossref_primary_10_1016_j_jtice_2018_05_044
crossref_primary_10_1371_journal_pone_0150146
crossref_primary_10_3390_vaccines9121382
crossref_primary_10_1016_j_ejmech_2017_04_038
crossref_primary_10_1007_s40272_017_0257_x
crossref_primary_10_1016_j_antiviral_2017_03_029
crossref_primary_10_1002_cjce_24197
crossref_primary_10_1073_pnas_1819197116
crossref_primary_10_3390_vaccines8020149
crossref_primary_10_1080_21645515_2017_1321183
crossref_primary_10_3390_vaccines7020051
crossref_primary_10_1080_21645515_2017_1373227
crossref_primary_10_3389_fimmu_2025_1539492
crossref_primary_10_1038_s41598_023_47690_9
crossref_primary_10_3389_fmicb_2016_00450
crossref_primary_10_1111_jcmm_15672
crossref_primary_10_3390_vaccines9020075
crossref_primary_10_1016_j_vaccine_2024_126408
crossref_primary_10_3390_vaccines12030287
crossref_primary_10_1016_j_cellsig_2025_111648
crossref_primary_10_1016_j_vacune_2018_10_001
crossref_primary_10_1128_CMR_00102_15
crossref_primary_10_3390_vaccines9020071
crossref_primary_10_1016_j_rvsc_2021_08_012
crossref_primary_10_11124_jbisrir_2014_1269
crossref_primary_10_3390_vaccines7020045
crossref_primary_10_3390_v13102090
crossref_primary_10_1007_s00705_018_3708_y
crossref_primary_10_1016_j_vaccine_2019_01_086
crossref_primary_10_1371_journal_pcbi_1006505
crossref_primary_10_1016_j_micpath_2024_107171
crossref_primary_10_1111_irv_12466
crossref_primary_10_3389_fchem_2018_00022
crossref_primary_10_1016_j_bbrc_2016_08_162
crossref_primary_10_3389_fimmu_2018_01093
crossref_primary_10_3390_v6051974
crossref_primary_10_3390_vaccines11081391
crossref_primary_10_1002_rmv_2243
crossref_primary_10_1080_14760584_2022_2072301
crossref_primary_10_2217_fvl_2016_0006
crossref_primary_10_1016_j_vaccine_2015_04_086
crossref_primary_10_1038_s41573_019_0056_x
crossref_primary_10_1080_02648725_2023_2191081
crossref_primary_10_1186_s13567_015_0174_3
crossref_primary_10_1186_s13104_015_1349_8
crossref_primary_10_3390_vaccines7010030
crossref_primary_10_3389_fimmu_2018_01568
crossref_primary_10_1177_2515135520908121
crossref_primary_10_1515_bams_2017_0009
crossref_primary_10_1126_science_342_6156_310_b
crossref_primary_10_1016_j_antiviral_2017_07_016
crossref_primary_10_1111_1348_0421_12775
crossref_primary_10_1177_1753465816646050
crossref_primary_10_3390_ani10122203
crossref_primary_10_3390_ijms17050666
crossref_primary_10_3390_pharmaceutics15082114
crossref_primary_10_1080_22221751_2019_1708214
crossref_primary_10_1021_acssynbio_9b00111
crossref_primary_10_1128_CVI_00548_16
crossref_primary_10_1016_j_cimid_2020_101601
crossref_primary_10_2174_1568026618666181112144745
crossref_primary_10_1016_j_micinf_2021_104878
crossref_primary_10_1128_JVI_00032_19
crossref_primary_10_1016_j_vaccine_2014_05_039
crossref_primary_10_1128_JVI_00720_17
crossref_primary_10_3389_fimmu_2024_1381508
crossref_primary_10_7774_cevr_2022_11_2_184
crossref_primary_10_3390_vaccines13010091
Cites_doi 10.1016/j.vaccine.2006.03.035
10.1016/S0264-410X(03)00071-9
10.1038/nature11414
10.1016/j.vaccine.2008.11.093
10.1128/JVI.02305-09
10.1016/j.vaccine.2009.05.014
10.1007/s12325-012-0025-9
10.1093/aje/kwm375
10.1016/j.vaccine.2010.03.067
10.1016/S0140-6736(04)17398-4
10.1007/s12325-011-0090-5
10.1016/j.vaccine.2012.01.016
10.1146/annurev.mi.47.100193.004001
10.1016/S0264-410X(00)00508-9
10.1086/527489
10.1056/NEJMoa043540
10.1038/nbt.2436
10.1016/S0022-3476(05)80489-5
10.1016/j.vaccine.2009.03.020
10.1093/infdis/jir837
10.1128/JVI.02330-12
10.1006/viro.1998.9534
10.1016/0264-410X(86)90049-6
10.1126/science.1125548
10.1016/j.vaccine.2008.11.003
10.1172/JCI41902
10.4049/jimmunol.159.11.5197
10.1016/0042-6822(89)90538-2
10.1016/j.vaccine.2012.11.074
10.1086/605505
10.1038/nsmb.1566
10.1016/j.vaccine.2010.12.092
10.1016/j.vaccine.2009.04.078
10.1128/iai.44.3.730-733.1984
10.1371/journal.pone.0003942
10.1128/CVI.05663-11
10.1086/590434
10.1016/j.vaccine.2011.05.041
10.1016/j.vaccine.2011.12.009
10.1016/j.vaccine.2011.08.016
10.1016/j.vaccine.2009.10.033
10.4161/hv.7.5.14821
10.1542/peds.2008-1035
10.1128/JVI.01563-08
10.1126/science.1083317
10.1016/0264-410X(95)92777-Y
10.1128/JVI.06325-11
10.1007/s12325-011-0042-0
10.1016/j.vaccine.2009.08.101
10.1016/S0140-6736(11)61051-9
10.1038/273238a0
10.1016/j.vaccine.2011.09.077
10.1056/NEJM197703102961012
10.1016/j.vaccine.2007.01.106
10.1016/j.vaccine.2004.02.021
10.1056/NEJMoa044021
10.1016/j.vaccine.2007.07.052
10.1086/599790
10.1016/j.vaccine.2009.01.116
10.1128/JVI.79.21.13811-13816.2005
10.1084/jem.20101352
10.1126/science.1204839
10.1016/S0140-6736(06)68656-X
10.1016/j.vaccine.2011.07.128
10.1016/0042-6822(76)90481-5
10.1016/j.vaccine.2004.07.043
10.1126/science.1213362
10.1371/journal.pone.0004384
10.1016/j.vaccine.2010.01.029
10.4161/hv.7.0.14560
10.1016/0008-8749(77)90170-8
10.4049/jimmunol.172.9.5598
10.1093/infdis/136.Supplement_3.S722
10.1146/annurev.immunol.17.1.51
10.1016/j.vaccine.2011.12.098
10.1038/311578a0
10.1111/j.1440-1843.2008.01247.x
10.1016/j.virusres.2011.09.022
10.1371/journal.pone.0033536
10.1016/S0140-6736(06)68076-8
10.1056/NEJMoa043555
10.1126/science.320661
10.1016/j.vaccine.2008.01.019
10.1111/j.1749-6632.2010.05829.x
10.1016/j.vaccine.2011.03.090
10.1084/jem.146.3.673
10.1128/CVI.05111-11
10.1016/j.virusres.2011.09.037
10.1073/pnas.0505587102
10.1038/303706a0
10.1128/CVI.00461-09
10.1073/pnas.1116200109
10.1016/j.vaccine.2011.01.039
10.1128/JVI.00050-06
10.1126/science.1205669
10.1128/JVI.05397-11
10.1016/j.virol.2010.12.003
10.1084/jem.159.2.365
10.1128/JVI.75.13.6154-6165.2001
10.1073/pnas.0811271106
10.1016/j.vaccine.2011.07.099
10.1038/213612a0
10.1126/science.1082305
10.1093/infdis/136.5.623
10.1038/440435a
10.1016/j.vaccine.2009.02.061
10.1016/S0264-410X(03)00456-0
10.1542/peds.2010-1920
10.1016/j.vaccine.2007.07.030
10.1016/j.vaccine.2011.05.001
10.4049/jimmunol.172.9.5553
10.1093/infdis/jir838
10.1093/cid/ciq015
10.1016/j.cell.2012.02.012
10.1073/pnas.1013387107
10.1136/pgmj.52.608.360
10.1128/JVI.02226-09
10.1016/S1473-3099(11)70295-X
10.1016/S1473-3099(12)70121-4
10.1056/NEJMra1000449
10.1016/S0140-6736(04)15892-3
10.1155/2010/517198
10.2165/00003495-200868110-00002
10.1002/ana.22184
10.1073/pnas.96.16.9345
10.1017/S002217240002458X
10.1128/mBio.00018-10
10.1056/NEJMoa1010331
10.1016/S0065-230X(06)95006-4
10.1016/S0076-6879(09)63014-7
10.1093/oxfordjournals.molbev.a004105
10.1016/S1473-3099(11)70240-7
10.1128/JVI.00781-09
10.1016/j.vaccine.2012.01.085
10.1073/pnas.0801367105
10.1016/S0198-8859(00)00105-1
10.1128/JVI.00970-08
10.1006/cimm.2001.1835
10.1016/j.chom.2010.05.009
10.4049/jimmunol.101.1.62
10.3201/eid/1706.091652
10.1073/pnas.070525997
10.1128/jvi.71.4.2772-2778.1997
10.1038/mt.2012.69
10.1017/S0022172400024591
10.1073/pnas.0903181106
10.1016/j.ijcard.2013.01.274
10.1016/j.it.2010.11.004
10.1056/NEJMoa0907650
10.1016/S0264-410X(98)00224-2
10.1056/NEJMoa0808652
10.1128/JVI.79.5.2814-2822.2005
10.1017/S0950268805003936
10.1073/pnas.1007465107
10.1128/JVI.00361-07
10.4049/jimmunol.1002845
10.1001/jama.292.11.1333
10.1086/605506
10.1016/j.vaccine.2012.04.089
10.1016/j.vaccine.2010.08.028
10.1002/(SICI)1099-1654(199910/12)9:4<237::AID-RMV252>3.0.CO;2-G
10.1016/S0264-410X(97)00031-5
10.1016/j.vaccine.2012.04.032
10.1016/j.immuni.2010.10.002
10.1016/j.vaccine.2009.08.032
10.1073/pnas.100133697
10.4161/hv.18757
10.1038/nature10831
10.4049/jimmunol.0902147
10.1016/j.vaccine.2009.11.043
10.4049/jimmunol.1101764
10.2807/ese.13.43.19017-en
10.1007/s00253-010-2742-9
10.1016/j.vaccine.2009.05.099
10.1016/j.vaccine.2012.02.071
10.1056/NEJM198307073090103
10.1371/journal.ppat.1000796
10.1023/A:1017919305501
10.3201/eid1209.05-0979
10.1016/j.vaccine.2005.07.098
10.1073/pnas.78.12.7639
10.1016/j.vaccine.2011.06.068
10.1093/cid/cis327
10.1002/eji.200324257
10.1093/cid/cir121
ContentType Journal Article
Copyright 2014 INIST-CNRS
Copyright © 2013, American Society for Microbiology. All Rights Reserved. 2013 American Society for Microbiology
Copyright_xml – notice: 2014 INIST-CNRS
– notice: Copyright © 2013, American Society for Microbiology. All Rights Reserved. 2013 American Society for Microbiology
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1128/CMR.00097-12
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1098-6618
EndPage 492
ExternalDocumentID PMC3719499
23824369
27516629
10_1128_CMR_00097_12
cmr_26_3_476
Genre Review
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: PHS HHS
  grantid: HHSN266200700005C
– fundername: NIAID NIH HHS
  grantid: HHSN266200700005C
GroupedDBID ---
.GJ
0R~
18M
29B
2WC
39C
4.4
53G
5GY
5VS
6J9
AAGFI
AAYXX
ACGFO
ADBBV
AENEX
AETEA
AGVNZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CITATION
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
H13
HYE
HZ~
KQ8
NEJ
O9-
OK1
P2P
RHI
RNS
RPM
RSF
TR2
W2D
W8F
WH7
WHG
WOQ
ZGI
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c505t-d4a6a1a9408b3b7de9c23e7ece44663fe61d0f995ae1bc37a3c5a1344a3175c3
ISSN 0893-8512
1098-6618
IngestDate Thu Aug 21 13:33:08 EDT 2025
Fri Jul 11 07:59:48 EDT 2025
Mon Jul 21 06:05:49 EDT 2025
Wed Apr 02 07:24:33 EDT 2025
Thu Apr 24 22:55:41 EDT 2025
Tue Jul 01 03:08:31 EDT 2025
Wed May 18 15:26:37 EDT 2016
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Infection
Vaccine
Review
Viral disease
Influenza
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c505t-d4a6a1a9408b3b7de9c23e7ece44663fe61d0f995ae1bc37a3c5a1344a3175c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://cmr.asm.org/content/cmr/26/3/476.full.pdf
PMID 23824369
PQID 1398423912
PQPubID 23479
PageCount 17
ParticipantIDs crossref_primary_10_1128_CMR_00097_12
crossref_citationtrail_10_1128_CMR_00097_12
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3719499
proquest_miscellaneous_1398423912
pascalfrancis_primary_27516629
pubmed_primary_23824369
highwire_asm_cmr_26_3_476
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-07-01
PublicationDateYYYYMMDD 2013-07-01
PublicationDate_xml – month: 07
  year: 2013
  text: 2013-07-01
  day: 01
PublicationDecade 2010
PublicationPlace Washington, DC
PublicationPlace_xml – name: Washington, DC
– name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Clinical Microbiology Reviews
PublicationTitleAlternate Clin Microbiol Rev
PublicationYear 2013
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_2_195_2
e_1_3_2_62_2
e_1_3_2_85_2
e_1_3_2_24_2
e_1_3_2_47_2
e_1_3_2_100_2
e_1_3_2_123_2
e_1_3_2_146_2
e_1_3_2_169_2
e_1_3_2_108_2
e_1_3_2_7_2
e_1_3_2_161_2
e_1_3_2_184_2
e_1_3_2_73_2
e_1_3_2_12_2
e_1_3_2_58_2
e_1_3_2_96_2
e_1_3_2_35_2
e_1_3_2_112_2
e_1_3_2_135_2
e_1_3_2_158_2
e_1_3_2_50_2
e_1_3_2_196_2
Romani N (e_1_3_2_115_2) 2012; 351
e_1_3_2_48_2
e_1_3_2_194_2
e_1_3_2_40_2
e_1_3_2_86_2
e_1_3_2_171_2
e_1_3_2_63_2
e_1_3_2_25_2
e_1_3_2_145_2
e_1_3_2_107_2
e_1_3_2_59_2
e_1_3_2_6_2
e_1_3_2_183_2
e_1_3_2_51_2
e_1_3_2_74_2
e_1_3_2_160_2
Centers for Disease Control and Prevention (e_1_3_2_2_2) 2010
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_97_2
e_1_3_2_134_2
Prausnitz MR (e_1_3_2_122_2) 2009; 333
e_1_3_2_157_2
e_1_3_2_111_2
e_1_3_2_119_2
e_1_3_2_151_2
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_68_2
e_1_3_2_125_2
e_1_3_2_148_2
e_1_3_2_60_2
e_1_3_2_83_2
e_1_3_2_102_2
e_1_3_2_163_2
e_1_3_2_186_2
Topham DJ (e_1_3_2_168_2) 1997; 159
e_1_3_2_18_2
e_1_3_2_140_2
e_1_3_2_10_2
e_1_3_2_33_2
e_1_3_2_79_2
e_1_3_2_114_2
e_1_3_2_137_2
e_1_3_2_94_2
e_1_3_2_71_2
e_1_3_2_152_2
e_1_3_2_175_2
e_1_3_2_198_2
Lee LY (e_1_3_2_172_2) 2008; 118
e_1_3_2_150_2
e_1_3_2_173_2
e_1_3_2_84_2
e_1_3_2_23_2
e_1_3_2_69_2
e_1_3_2_46_2
e_1_3_2_124_2
e_1_3_2_147_2
e_1_3_2_61_2
e_1_3_2_101_2
e_1_3_2_185_2
e_1_3_2_109_2
Styk B (e_1_3_2_31_2) 1979; 23
Francis T (e_1_3_2_37_2) 1953; 8
e_1_3_2_19_2
e_1_3_2_162_2
Wright PF (e_1_3_2_14_2) 2007
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_57_2
e_1_3_2_95_2
e_1_3_2_4_2
e_1_3_2_113_2
e_1_3_2_159_2
e_1_3_2_136_2
e_1_3_2_72_2
e_1_3_2_174_2
e_1_3_2_197_2
e_1_3_2_28_2
e_1_3_2_191_2
e_1_3_2_20_2
e_1_3_2_66_2
e_1_3_2_89_2
e_1_3_2_104_2
e_1_3_2_142_2
e_1_3_2_165_2
e_1_3_2_188_2
Maassab HF (e_1_3_2_56_2) 1990; 14
e_1_3_2_81_2
e_1_3_2_127_2
e_1_3_2_16_2
e_1_3_2_54_2
e_1_3_2_180_2
e_1_3_2_3_2
e_1_3_2_77_2
e_1_3_2_92_2
e_1_3_2_131_2
e_1_3_2_154_2
e_1_3_2_177_2
e_1_3_2_116_2
e_1_3_2_139_2
e_1_3_2_190_2
e_1_3_2_29_2
e_1_3_2_21_2
e_1_3_2_44_2
e_1_3_2_67_2
e_1_3_2_126_2
e_1_3_2_82_2
e_1_3_2_103_2
e_1_3_2_141_2
e_1_3_2_187_2
e_1_3_2_164_2
e_1_3_2_149_2
e_1_3_2_17_2
e_1_3_2_32_2
e_1_3_2_55_2
e_1_3_2_78_2
Reber AJ (e_1_3_2_5_2) 2012; 3
e_1_3_2_93_2
e_1_3_2_130_2
e_1_3_2_176_2
e_1_3_2_153_2
e_1_3_2_138_2
e_1_3_2_26_2
e_1_3_2_49_2
Fiore AE (e_1_3_2_39_2) 2010; 59
e_1_3_2_193_2
e_1_3_2_41_2
e_1_3_2_64_2
e_1_3_2_87_2
e_1_3_2_170_2
e_1_3_2_167_2
e_1_3_2_121_2
e_1_3_2_144_2
e_1_3_2_106_2
e_1_3_2_129_2
e_1_3_2_9_2
Centers for Disease Control and Prevention (e_1_3_2_70_2) 2012; 61
e_1_3_2_75_2
e_1_3_2_182_2
e_1_3_2_52_2
Duxbury AE (e_1_3_2_43_2) 1968; 101
e_1_3_2_98_2
e_1_3_2_156_2
e_1_3_2_179_2
e_1_3_2_110_2
e_1_3_2_133_2
e_1_3_2_90_2
e_1_3_2_118_2
e_1_3_2_27_2
e_1_3_2_192_2
e_1_3_2_65_2
e_1_3_2_42_2
e_1_3_2_88_2
e_1_3_2_189_2
e_1_3_2_120_2
e_1_3_2_166_2
e_1_3_2_80_2
e_1_3_2_143_2
e_1_3_2_105_2
e_1_3_2_128_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_30_2
e_1_3_2_53_2
e_1_3_2_76_2
e_1_3_2_99_2
e_1_3_2_181_2
e_1_3_2_91_2
e_1_3_2_178_2
e_1_3_2_155_2
e_1_3_2_132_2
e_1_3_2_117_2
21237476 - Virology. 2011 Mar 15;411(2):229-36
21147034 - Trends Immunol. 2011 Jan;32(1):34-41
22032844 - Lancet Infect Dis. 2012 Jan;12(1):36-44
306072 - Nature. 1978 May 18;273(5659):238-9
5662705 - J Immunol. 1968 Jul;101(1):62-7
22326774 - Vaccine. 2012 Mar 28;30(15):2535-42
20798667 - MMWR Morb Mortal Wkly Rep. 2010 Aug 27;59(33):1057-62
22895385 - MMWR Morb Mortal Wkly Rep. 2012 Aug 17;61(32):613-8
21464195 - Pediatrics. 2011 May;127(5):e1161-8
10801978 - Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13
16860659 - Adv Cancer Res. 2006;95:203-47
20713260 - Vaccine. 2010 Sep 7;28 Suppl 4:D45-53
6040602 - Nature. 1967 Feb 11;213(5076):612-4
20615991 - Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13701-6
15064027 - Lancet. 2004 Apr 3;363(9415):1099-103
23228813 - Vaccine. 2013 Jan 21;31(5):770-6
20865762 - Ann Neurol. 2010 Nov;68(5):762-6
21963677 - Virus Res. 2011 Dec;162(1-2):19-30
20617311 - Appl Microbiol Biotechnol. 2010 Sep;88(2):461-75
20810680 - Clin Vaccine Immunol. 2010 Nov;17(11):1817-9
1068195 - J Hyg (Lond). 1976 Oct;77(2):161-72
10773346 - Hum Immunol. 2000 May;61(5):438-52
20071564 - J Virol. 2010 Apr;84(7):3312-9
11599686 - Eur J Epidemiol. 2001;17(2):135-40
22722205 - Nature. 2012 Jun 21;486(7403):420-8
20195520 - PLoS Pathog. 2010 Feb;6(2):e1000796
21715575 - Clin Vaccine Immunol. 2011 Aug;18(8):1358-64
6602294 - N Engl J Med. 1983 Jul 7;309(1):13-7
21169548 - J Immunol. 2011 Jan 15;186(2):1022-31
320661 - Science. 1977 Mar 4;195(4281):834-47
16143432 - Vaccine. 2005 Dec 30;23(50):5751-9
10073729 - Vaccine. 1999 Feb 5;17(5):497-507
22275400 - J Infect Dis. 2012 Mar 1;205(5):697-9
19450640 - Vaccine. 2009 Dec 9;27(52):7451-8
19745215 - N Engl J Med. 2009 Dec 17;361(25):2424-35
22575166 - Vaccine. 2012 Jun 29;30(31):4655-60
18627206 - Drugs. 2008;68(11):1483-91
21798894 - Science. 2011 Aug 12;333(6044):850-6
19234466 - Nat Struct Mol Biol. 2009 Mar;16(3):265-73
22226861 - Vaccine. 2012 Mar 2;30(11):1993-8
22265860 - Vaccine. 2012 Feb 27;30(10):1759-66
21624416 - Vaccine. 2011 Jul 18;29(32):5145-52
15297047 - Vaccine. 2004 Aug 13;22(23-24):2993-3003
20389023 - J Clin Invest. 2010 May;120(5):1663-73
21821086 - Vaccine. 2011 Oct 6;29(43):7559-71
1993950 - J Pediatr. 1991 Feb;118(2):235-8
16554799 - Nature. 2006 Mar 23;440(7083):435-6
9927581 - Virology. 1999 Feb 1;254(1):138-46
1068196 - J Hyg (Lond). 1976 Oct;77(2):173-80
21968444 - Vaccine. 2011 Nov 8;29(48):8788-801
20445182 - N Engl J Med. 2010 May 6;362(18):1708-19
22192847 - Vaccine. 2012 Feb 8;30(7):1388-96
19892174 - Methods Enzymol. 2009;463:191-222
19095024 - Vaccine. 2009 Feb 11;27(7):1101-10
17337102 - Vaccine. 2007 May 10;25(19):3871-8
19540952 - Vaccine. 2009 Aug 6;27(36):4953-60
19776407 - N Engl J Med. 2009 Sep 24;361(13):1260-7
23474244 - Int J Cardiol. 2013 Sep 10;167(6):2397-403
335000 - J Infect Dis. 1977 Nov;136(5):623-32
10430945 - Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9345-50
16556800 - Science. 2006 Apr 21;312(5772):399
19673651 - J Infect Dis. 2009 Sep 15;200(6):841-8
18294741 - Vaccine. 2008 Mar 17;26(12):1525-9
13094502 - Bull World Health Organ. 1953;8(5-6):725-41
14505903 - Vaccine. 2003 Oct 1;21(27-30):4234-7
21148512 - Clin Infect Dis. 2011 Jan 1;52(1):1-7
22738893 - Lancet Infect Dis. 2012 Sep;12(9):687-95
9548456 - J Immunol. 1997 Dec 1;159(11):5197-200
20117262 - Vaccine. 2010 Mar 16;28(13):2565-72
20542248 - Cell Host Microbe. 2010 Jun 25;7(6):440-51
18842709 - J Virol. 2008 Dec;82(24):12241-51
16473124 - Lancet. 2006 Feb 11;367(9509):475-81
21251008 - Ann N Y Acad Sci. 2011 Jan;1217:178-90
15100303 - J Immunol. 2004 May 1;172(9):5598-605
18947524 - Euro Surveill. 2008 Oct 23;13(43). pii: 19017
19849996 - Vaccine. 2009 Dec 9;27(52):7304-12
22275399 - J Infect Dis. 2012 Mar 1;205(5):703-12
18652550 - J Infect Dis. 2008 Sep 1;198(5):650-8
15620476 - Vaccine. 2005 Jan 11;23(8):1029-36
18230677 - Am J Epidemiol. 2008 Apr 1;167(7):775-85
16823947 - Vaccine. 2006 Jun 5;24(23):4897-4900
1258359 - Virology. 1976 Feb;69(2):511-22
19122146 - Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):540-5
836542 - N Engl J Med. 1977 Mar 10;296(10):567-8
303150 - Cell Immunol. 1977 Oct;33(2):423-36
19751689 - Vaccine. 2009 Nov 16;27(49):6959-65
15525713 - N Engl J Med. 2004 Nov 25;351(22):2286-94
16227302 - J Virol. 2005 Nov;79(21):13811-6
19768415 - Curr Top Microbiol Immunol. 2009;333:369-93
20394719 - Vaccine. 2010 May 21;28(23):3929-35
11390617 - J Virol. 2001 Jul;75(13):6154-65
20369059 - Clin Dev Immunol. 2010;2010:517198
18413603 - Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):5986-91
21596084 - Vaccine. 2011 Jul 12;29(31):4897-902
22078723 - Lancet. 2011 Dec 3;378(9807):1917-30
8578816 - Vaccine. 1995;13(15):1399-402
21723354 - Vaccine. 2011 Aug 11;29(35):5911-8
19673652 - J Infect Dis. 2009 Sep 15;200(6):849-57
21422814 - Hum Vaccin. 2011 May;7(5):539-48
21481325 - Vaccine. 2011 May 23;29(23):3951-61
20689501 - MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1-62
19508159 - J Infect Dis. 2009 Jul 15;200(2):172-80
22500272 - Aging Dis. 2012 Feb;3(1):68-90
15709000 - J Virol. 2005 Mar;79(5):2814-22
19171569 - Pediatrics. 2009 Feb;123(2):e186-92
22470453 - PLoS One. 2012;7(3):e33536
9302747 - Vaccine. 1997 Aug-Sep;15(12-13):1372-8
19416838 - Proc Natl Acad Sci U S A. 2009 May 12;106(19):7962-7
959116 - Postgrad Med J. 1976 Jun;52(608):360-7
9060631 - J Virol. 1997 Apr;71(4):2772-8
3524050 - Vaccine. 1986 Jun;4(2):114-8
11919291 - Mol Biol Evol. 2002 Apr;19(4):501-9
12686093 - Vaccine. 2003 May 1;21(16):1776-9
606797 - J Infect Dis. 1977 Dec;136 Suppl:S722-30
35954 - Acta Virol. 1979 Jan;23(1):1-8
19587040 - J Virol. 2009 Sep;83(18):9296-303
21737702 - Science. 2011 Aug 12;333(6044):843-50
17728025 - Vaccine. 2007 Oct 10;25(41):7017-30
2741346 - Virology. 1989 Jul;171(1):275-9
10725408 - Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4309-14
21968298 - Virus Res. 2011 Dec;162(1-2):31-8
12690202 - Science. 2003 Apr 11;300(5617):339-42
21975270 - Lancet Infect Dis. 2011 Dec;11(12):916-24
22718815 - J Virol. 2012 Sep;86(17):9233-43
15100298 - J Immunol. 2004 May 1;172(9):5553-60
22351935 - J Immunol. 2012 Apr 1;188(7):3088-98
19410623 - Vaccine. 2009 Jun 24;27(31):4099-103
19716456 - Vaccine. 2009 Nov 5;27(47):6589-94
20956293 - Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18979-84
21245655 - Hum Vaccin. 2011 Jan-Feb;7 Suppl:29-40
21460314 - Clin Infect Dis. 2011 Apr 15;52(8):1003-9
15525714 - N Engl J Med. 2004 Nov 25;351(22):2295-301
302303 - J Exp Med. 1977 Sep 1;146(3):673-89
19368768 - Vaccine. 2009 Mar 18;27(13):1889-97
10358753 - Annu Rev Immunol. 1999;17:51-88
20534862 - J Virol. 2010 Sep;84(17):8369-88
15541448 - Lancet. 2004 Nov 13-19;364(9447):1757-65
2222834 - Adv Biotechnol Processes. 1990;14:203-42
20689752 - MBio. 2010 May 18;1(1):null
21029960 - Immunity. 2010 Oct 29;33(4):492-503
19197383 - PLoS One. 2009;4(2):e4384
16940524 - J Virol. 2006 Sep;80(18):9134-43
21816199 - Vaccine. 2011 Oct 13;29(44):7826-34
22982990 - Nature. 2012 Sep 27;489(7417):526-32
15668219 - N Engl J Med. 2005 Jan 27;352(4):333-40
6332992 - Nature. 1984 Oct 11-17;311(5986):578-9
23077318 - J Virol. 2013 Jan;87(1):363-71
15367555 - JAMA. 2004 Sep 15;292(11):1333-40
21242525 - J Immunol. 2011 Feb 15;186(4):2422-9
6174976 - Proc Natl Acad Sci U S A. 1981 Dec;78(12):7639-43
21995388 - N Engl J Med. 2011 Oct 13;365(15):1406-16
21220454 - J Exp Med. 2011 Jan 17;208(1):181-93
16714186 - Lancet. 2006 May 20;367(9523):1657-64
21751080 - Adv Ther. 2011 Aug;28(8):640-9
10578119 - Rev Med Virol. 1999 Oct-Dec;9(4):237-44
6724694 - Infect Immun. 1984 Jun;44(3):730-3
19840663 - Vaccine. 2009 Oct 23;27(45):6296-9
6198430 - J Exp Med. 1984 Feb 1;159(2):365-77
23159882 - Nat Biotechnol. 2012 Dec;30(12):1210-6
22371588 - Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4269-74
12690201 - Science. 2003 Apr 11;300(5617):337-9
21749769 - Emerg Infect Dis. 2011 Jun;17(6):1056-9
22537989 - Vaccine. 2012 Jul 6;30(32):4884-91
21835220 - Vaccine. 2011 Oct 13;29(44):7733-9
14971045 - Eur J Immunol. 2004 Jan;34(1):194-9
8257115 - Annu Rev Microbiol. 1993;47:765-90
6190093 - Nature. 1983 Jun 23-29;303(5919):706-9
11591118 - Cell Immunol. 2001 Aug 1;211(2):143-53
21232649 - Vaccine. 2011 Mar 3;29(11):2010
22330956 - Hum Vaccin Immunother. 2012 Mar;8(3):411-4
18802496 - J Clin Invest. 2008 Oct;118(10):3478-90
18260764 - J Infect Dis. 2008 Mar 1;197(5):667-75
19027046 - Vaccine. 2009 Jan 29;27(5):786-91
16267134 - Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16825-9
22228256 - Adv Ther. 2012 Jan;29(1):41-52
22406460 - Vaccine. 2012 Nov 6;30(48):6946-54
18366521 - Respirology. 2008 Mar;13 Suppl 1:S10-3
18768983 - J Virol. 2008 Nov;82(21):10502-9
19368793 - Vaccine. 2009 Apr 21;27(18):2506-12
21253784 - Curr Top Microbiol Immunol. 2012;351:113-38
22508490 - Mol Ther. 2012 Jul;20(7):1472-80
17475660 - J Virol. 2007 Jul;81(13):7111-23
22956656 - Clin Vaccine Immunol. 2012 Nov;19(11):1792-7
17766014 - Vaccine. 2007 Oct 10;25(41):7065-74
22424235 - Cell. 2012 Mar 16;148(6):1284-92
22678831 - Adv Ther. 2012 Jun;29(6):562-77
22441650 - Clin Infect Dis. 2012 Jul;55(1):19-25
16050515 - Epidemiol Infect. 2005 Aug;133(4):687-93
19079604 - PLoS One. 2008;3(12):e3942
20004635 - Vaccine. 2010 Feb 3;28(5):1156-67
16494711 - Emerg Infect Dis. 2006 Jan;12(1):15-22
21865387 - J Virol. 2011 Nov;85(21):11048-57
22723413 - Science. 2012 Jun 22;336(6088):1534-41
21277410 - Vaccine. 2011 Mar 9;29(12):2272-8
11257414 - Vaccine. 2001 Mar 21;19(17-19):2716-21
References_xml – ident: e_1_3_2_34_2
  doi: 10.1016/j.vaccine.2006.03.035
– ident: e_1_3_2_68_2
  doi: 10.1016/S0264-410X(03)00071-9
– ident: e_1_3_2_198_2
  doi: 10.1038/nature11414
– ident: e_1_3_2_60_2
  doi: 10.1016/j.vaccine.2008.11.093
– ident: e_1_3_2_110_2
  doi: 10.1128/JVI.02305-09
– ident: e_1_3_2_148_2
  doi: 10.1016/j.vaccine.2009.05.014
– ident: e_1_3_2_125_2
  doi: 10.1007/s12325-012-0025-9
– ident: e_1_3_2_21_2
  doi: 10.1093/aje/kwm375
– ident: e_1_3_2_41_2
  doi: 10.1016/j.vaccine.2010.03.067
– ident: e_1_3_2_132_2
  doi: 10.1016/S0140-6736(04)17398-4
– ident: e_1_3_2_126_2
  doi: 10.1007/s12325-011-0090-5
– ident: e_1_3_2_131_2
  doi: 10.1016/j.vaccine.2012.01.016
– ident: e_1_3_2_81_2
  doi: 10.1146/annurev.mi.47.100193.004001
– ident: e_1_3_2_75_2
  doi: 10.1016/S0264-410X(00)00508-9
– ident: e_1_3_2_91_2
  doi: 10.1086/527489
– ident: e_1_3_2_120_2
  doi: 10.1056/NEJMoa043540
– ident: e_1_3_2_158_2
  doi: 10.1038/nbt.2436
– ident: e_1_3_2_9_2
  doi: 10.1016/S0022-3476(05)80489-5
– ident: e_1_3_2_149_2
  doi: 10.1016/j.vaccine.2009.03.020
– ident: e_1_3_2_128_2
  doi: 10.1093/infdis/jir837
– ident: e_1_3_2_147_2
  doi: 10.1128/JVI.02330-12
– ident: e_1_3_2_33_2
  doi: 10.1006/viro.1998.9534
– ident: e_1_3_2_65_2
  doi: 10.1016/0264-410X(86)90049-6
– ident: e_1_3_2_63_2
  doi: 10.1126/science.1125548
– ident: e_1_3_2_78_2
  doi: 10.1016/j.vaccine.2008.11.003
– ident: e_1_3_2_32_2
  doi: 10.1172/JCI41902
– volume: 159
  start-page: 5197
  year: 1997
  ident: e_1_3_2_168_2
  article-title: CD8+ T cells clear influenza virus by perforin or Fas-dependent processes
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.159.11.5197
– ident: e_1_3_2_71_2
  doi: 10.1016/0042-6822(89)90538-2
– ident: e_1_3_2_53_2
  doi: 10.1016/j.vaccine.2012.11.074
– ident: e_1_3_2_80_2
  doi: 10.1086/605505
– ident: e_1_3_2_186_2
  doi: 10.1038/nsmb.1566
– ident: e_1_3_2_107_2
  doi: 10.1016/j.vaccine.2010.12.092
– ident: e_1_3_2_97_2
  doi: 10.1016/j.vaccine.2009.04.078
– ident: e_1_3_2_66_2
  doi: 10.1128/iai.44.3.730-733.1984
– ident: e_1_3_2_187_2
  doi: 10.1371/journal.pone.0003942
– ident: e_1_3_2_154_2
  doi: 10.1128/CVI.05663-11
– ident: e_1_3_2_117_2
  doi: 10.1086/590434
– ident: e_1_3_2_164_2
  doi: 10.1016/j.vaccine.2011.05.041
– ident: e_1_3_2_77_2
  doi: 10.1016/j.vaccine.2011.12.009
– ident: e_1_3_2_103_2
  doi: 10.1016/j.vaccine.2011.08.016
– ident: e_1_3_2_118_2
  doi: 10.1016/j.vaccine.2009.10.033
– ident: e_1_3_2_104_2
  doi: 10.4161/hv.7.5.14821
– ident: e_1_3_2_69_2
  doi: 10.1542/peds.2008-1035
– ident: e_1_3_2_171_2
  doi: 10.1128/JVI.01563-08
– ident: e_1_3_2_170_2
  doi: 10.1126/science.1083317
– ident: e_1_3_2_160_2
  doi: 10.1016/0264-410X(95)92777-Y
– start-page: 1691
  volume-title: Fields virology, 5th ed
  year: 2007
  ident: e_1_3_2_14_2
– ident: e_1_3_2_29_2
  doi: 10.1128/JVI.06325-11
– ident: e_1_3_2_124_2
  doi: 10.1007/s12325-011-0042-0
– ident: e_1_3_2_105_2
  doi: 10.1016/j.vaccine.2009.08.101
– ident: e_1_3_2_4_2
  doi: 10.1016/S0140-6736(11)61051-9
– ident: e_1_3_2_24_2
  doi: 10.1038/273238a0
– ident: e_1_3_2_121_2
  doi: 10.1016/j.vaccine.2011.09.077
– ident: e_1_3_2_50_2
  doi: 10.1056/NEJM197703102961012
– ident: e_1_3_2_141_2
  doi: 10.1016/j.vaccine.2007.01.106
– ident: e_1_3_2_163_2
  doi: 10.1016/j.vaccine.2004.02.021
– ident: e_1_3_2_17_2
  doi: 10.1056/NEJMoa044021
– ident: e_1_3_2_179_2
  doi: 10.1016/j.vaccine.2007.07.052
– ident: e_1_3_2_127_2
  doi: 10.1086/599790
– ident: e_1_3_2_76_2
  doi: 10.1016/j.vaccine.2009.01.116
– ident: e_1_3_2_88_2
  doi: 10.1128/JVI.79.21.13811-13816.2005
– ident: e_1_3_2_193_2
  doi: 10.1084/jem.20101352
– ident: e_1_3_2_189_2
  doi: 10.1126/science.1204839
– ident: e_1_3_2_90_2
  doi: 10.1016/S0140-6736(06)68656-X
– ident: e_1_3_2_133_2
  doi: 10.1016/j.vaccine.2011.07.128
– ident: e_1_3_2_44_2
  doi: 10.1016/0042-6822(76)90481-5
– ident: e_1_3_2_150_2
  doi: 10.1016/j.vaccine.2004.07.043
– ident: e_1_3_2_19_2
  doi: 10.1126/science.1213362
– ident: e_1_3_2_8_2
– ident: e_1_3_2_94_2
  doi: 10.1371/journal.pone.0004384
– ident: e_1_3_2_156_2
  doi: 10.1016/j.vaccine.2010.01.029
– volume: 3
  start-page: 68
  year: 2012
  ident: e_1_3_2_5_2
  article-title: Immunosenescence and challenges of vaccination against influenza in the aging population
  publication-title: Aging Dis.
– volume: 61
  start-page: 613
  year: 2012
  ident: e_1_3_2_70_2
  article-title: Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2012-13 influenza season
  publication-title: MMWR Morb. Mortal. Wkly. Rep.
– ident: e_1_3_2_116_2
  doi: 10.4161/hv.7.0.14560
– ident: e_1_3_2_165_2
  doi: 10.1016/0008-8749(77)90170-8
– ident: e_1_3_2_161_2
  doi: 10.4049/jimmunol.172.9.5598
– ident: e_1_3_2_48_2
  doi: 10.1093/infdis/136.Supplement_3.S722
– ident: e_1_3_2_174_2
  doi: 10.1146/annurev.immunol.17.1.51
– ident: e_1_3_2_51_2
  doi: 10.1016/j.vaccine.2011.12.098
– ident: e_1_3_2_177_2
  doi: 10.1038/311578a0
– ident: e_1_3_2_11_2
  doi: 10.1111/j.1440-1843.2008.01247.x
– volume: 118
  start-page: 3478
  year: 2008
  ident: e_1_3_2_172_2
  article-title: Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals
  publication-title: J. Clin. Invest.
– ident: e_1_3_2_23_2
  doi: 10.1016/j.virusres.2011.09.022
– ident: e_1_3_2_108_2
  doi: 10.1371/journal.pone.0033536
– volume: 333
  start-page: 369
  year: 2009
  ident: e_1_3_2_122_2
  article-title: Microneedle-based vaccines
  publication-title: Curr. Top. Microbiol. Immunol.
– ident: e_1_3_2_146_2
  doi: 10.1016/S0140-6736(06)68076-8
– ident: e_1_3_2_119_2
  doi: 10.1056/NEJMoa043555
– ident: e_1_3_2_36_2
  doi: 10.1126/science.320661
– ident: e_1_3_2_98_2
  doi: 10.1016/j.vaccine.2008.01.019
– ident: e_1_3_2_30_2
  doi: 10.1111/j.1749-6632.2010.05829.x
– ident: e_1_3_2_181_2
  doi: 10.1016/j.vaccine.2011.03.090
– ident: e_1_3_2_166_2
  doi: 10.1084/jem.146.3.673
– ident: e_1_3_2_42_2
  doi: 10.1128/CVI.05111-11
– ident: e_1_3_2_140_2
  doi: 10.1016/j.virusres.2011.09.037
– ident: e_1_3_2_84_2
  doi: 10.1073/pnas.0505587102
– ident: e_1_3_2_72_2
  doi: 10.1038/303706a0
– ident: e_1_3_2_93_2
  doi: 10.1128/CVI.00461-09
– ident: e_1_3_2_15_2
  doi: 10.1073/pnas.1116200109
– ident: e_1_3_2_134_2
  doi: 10.1016/j.vaccine.2011.01.039
– ident: e_1_3_2_136_2
  doi: 10.1128/JVI.00050-06
– ident: e_1_3_2_190_2
  doi: 10.1126/science.1205669
– ident: e_1_3_2_192_2
  doi: 10.1128/JVI.05397-11
– ident: e_1_3_2_159_2
  doi: 10.1016/j.virol.2010.12.003
– volume: 59
  start-page: 1
  issue: 8
  year: 2010
  ident: e_1_3_2_39_2
  article-title: Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010
  publication-title: MMWR Recommend. Rep
– ident: e_1_3_2_27_2
  doi: 10.1084/jem.159.2.365
– ident: e_1_3_2_137_2
  doi: 10.1128/JVI.75.13.6154-6165.2001
– ident: e_1_3_2_26_2
  doi: 10.1073/pnas.0811271106
– ident: e_1_3_2_145_2
  doi: 10.1016/j.vaccine.2011.07.099
– ident: e_1_3_2_54_2
  doi: 10.1038/213612a0
– ident: e_1_3_2_169_2
  doi: 10.1126/science.1082305
– ident: e_1_3_2_49_2
  doi: 10.1093/infdis/136.5.623
– ident: e_1_3_2_62_2
  doi: 10.1038/440435a
– ident: e_1_3_2_157_2
  doi: 10.1016/j.vaccine.2009.02.061
– ident: e_1_3_2_100_2
  doi: 10.1016/S0264-410X(03)00456-0
– ident: e_1_3_2_106_2
  doi: 10.1542/peds.2010-1920
– ident: e_1_3_2_38_2
  doi: 10.1016/j.vaccine.2007.07.030
– ident: e_1_3_2_113_2
  doi: 10.1016/j.vaccine.2011.05.001
– ident: e_1_3_2_175_2
  doi: 10.4049/jimmunol.172.9.5553
– ident: e_1_3_2_129_2
  doi: 10.1093/infdis/jir838
– ident: e_1_3_2_151_2
  doi: 10.1093/cid/ciq015
– ident: e_1_3_2_109_2
  doi: 10.1016/j.cell.2012.02.012
– ident: e_1_3_2_197_2
  doi: 10.1073/pnas.1013387107
– ident: e_1_3_2_45_2
  doi: 10.1136/pgmj.52.608.360
– ident: e_1_3_2_28_2
  doi: 10.1128/JVI.02226-09
– ident: e_1_3_2_61_2
  doi: 10.1016/S1473-3099(11)70295-X
– ident: e_1_3_2_7_2
  doi: 10.1016/S1473-3099(12)70121-4
– ident: e_1_3_2_12_2
  doi: 10.1056/NEJMra1000449
– ident: e_1_3_2_86_2
  doi: 10.1016/S0140-6736(04)15892-3
– ident: e_1_3_2_96_2
  doi: 10.1155/2010/517198
– ident: e_1_3_2_74_2
  doi: 10.2165/00003495-200868110-00002
– ident: e_1_3_2_13_2
  doi: 10.1002/ana.22184
– ident: e_1_3_2_83_2
  doi: 10.1073/pnas.96.16.9345
– ident: e_1_3_2_47_2
  doi: 10.1017/S002217240002458X
– ident: e_1_3_2_195_2
  doi: 10.1128/mBio.00018-10
– ident: e_1_3_2_102_2
  doi: 10.1056/NEJMoa1010331
– ident: e_1_3_2_173_2
  doi: 10.1016/S0065-230X(06)95006-4
– ident: e_1_3_2_130_2
  doi: 10.1016/S0076-6879(09)63014-7
– ident: e_1_3_2_183_2
  doi: 10.1093/oxfordjournals.molbev.a004105
– ident: e_1_3_2_155_2
  doi: 10.1016/S1473-3099(11)70240-7
– ident: e_1_3_2_85_2
  doi: 10.1128/JVI.00781-09
– ident: e_1_3_2_143_2
  doi: 10.1016/j.vaccine.2012.01.085
– ident: e_1_3_2_188_2
  doi: 10.1073/pnas.0801367105
– ident: e_1_3_2_25_2
  doi: 10.1016/S0198-8859(00)00105-1
– ident: e_1_3_2_87_2
  doi: 10.1128/JVI.00970-08
– ident: e_1_3_2_180_2
  doi: 10.1006/cimm.2001.1835
– ident: e_1_3_2_20_2
  doi: 10.1016/j.chom.2010.05.009
– volume: 101
  start-page: 62
  year: 1968
  ident: e_1_3_2_43_2
  article-title: Antibody response in humans to deoxycholate-treated influenza virus vaccine
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.101.1.62
– ident: e_1_3_2_16_2
  doi: 10.3201/eid/1706.091652
– ident: e_1_3_2_59_2
  doi: 10.1073/pnas.070525997
– ident: e_1_3_2_58_2
  doi: 10.1128/jvi.71.4.2772-2778.1997
– ident: e_1_3_2_123_2
  doi: 10.1038/mt.2012.69
– ident: e_1_3_2_46_2
  doi: 10.1017/S0022172400024591
– ident: e_1_3_2_95_2
  doi: 10.1073/pnas.0903181106
– ident: e_1_3_2_10_2
  doi: 10.1016/j.ijcard.2013.01.274
– ident: e_1_3_2_22_2
  doi: 10.1016/j.it.2010.11.004
– ident: e_1_3_2_92_2
  doi: 10.1056/NEJMoa0907650
– ident: e_1_3_2_178_2
  doi: 10.1016/S0264-410X(98)00224-2
– ident: e_1_3_2_35_2
  doi: 10.1056/NEJMoa0808652
– ident: e_1_3_2_184_2
  doi: 10.1128/JVI.79.5.2814-2822.2005
– ident: e_1_3_2_101_2
  doi: 10.1017/S0950268805003936
– ident: e_1_3_2_196_2
  doi: 10.1073/pnas.1007465107
– ident: e_1_3_2_139_2
  doi: 10.1128/JVI.00361-07
– ident: e_1_3_2_112_2
  doi: 10.4049/jimmunol.1002845
– ident: e_1_3_2_3_2
  doi: 10.1001/jama.292.11.1333
– ident: e_1_3_2_79_2
  doi: 10.1086/605506
– ident: e_1_3_2_182_2
  doi: 10.1016/j.vaccine.2012.04.089
– ident: e_1_3_2_52_2
  doi: 10.1016/j.vaccine.2010.08.028
– ident: e_1_3_2_55_2
  doi: 10.1002/(SICI)1099-1654(199910/12)9:4<237::AID-RMV252>3.0.CO;2-G
– ident: e_1_3_2_57_2
  doi: 10.1016/S0264-410X(97)00031-5
– ident: e_1_3_2_114_2
  doi: 10.1016/j.vaccine.2012.04.032
– ident: e_1_3_2_89_2
  doi: 10.1016/j.immuni.2010.10.002
– ident: e_1_3_2_135_2
  doi: 10.1016/j.vaccine.2009.08.032
– ident: e_1_3_2_82_2
  doi: 10.1073/pnas.100133697
– ident: e_1_3_2_144_2
  doi: 10.4161/hv.18757
– ident: e_1_3_2_18_2
  doi: 10.1038/nature10831
– ident: e_1_3_2_162_2
  doi: 10.4049/jimmunol.0902147
– ident: e_1_3_2_67_2
  doi: 10.1016/j.vaccine.2009.11.043
– ident: e_1_3_2_111_2
  doi: 10.4049/jimmunol.1101764
– ident: e_1_3_2_40_2
  doi: 10.2807/ese.13.43.19017-en
– ident: e_1_3_2_73_2
  doi: 10.1007/s00253-010-2742-9
– ident: e_1_3_2_64_2
  doi: 10.1016/j.vaccine.2009.05.099
– ident: e_1_3_2_153_2
  doi: 10.1016/j.vaccine.2012.02.071
– ident: e_1_3_2_167_2
  doi: 10.1056/NEJM198307073090103
– start-page: 1057
  volume-title: MMWR Morb. Mortal. Wkly. Rep.
  year: 2010
  ident: e_1_3_2_2_2
– volume: 351
  start-page: 113
  year: 2012
  ident: e_1_3_2_115_2
  article-title: Targeting skin dendritic cells to improve intradermal vaccination
  publication-title: Curr. Top. Microbiol. Immunol.
– volume: 23
  start-page: 1
  year: 1979
  ident: e_1_3_2_31_2
  article-title: Antigenic glycopolypeptides HA1 and HA2 of influenza virus haemagglutinin. III. Reactivity with human convalescent sera
  publication-title: Acta Virol.
– ident: e_1_3_2_194_2
  doi: 10.1371/journal.ppat.1000796
– volume: 14
  start-page: 203
  year: 1990
  ident: e_1_3_2_56_2
  article-title: Cold-adapted influenza viruses for use as live vaccines for man
  publication-title: Adv. Biotechnol. Processes
– ident: e_1_3_2_99_2
  doi: 10.1023/A:1017919305501
– ident: e_1_3_2_6_2
  doi: 10.3201/eid1209.05-0979
– ident: e_1_3_2_138_2
  doi: 10.1016/j.vaccine.2005.07.098
– ident: e_1_3_2_185_2
  doi: 10.1073/pnas.78.12.7639
– volume: 8
  start-page: 725
  year: 1953
  ident: e_1_3_2_37_2
  article-title: Vaccination against influenza
  publication-title: Bull. World Health Organ.
– ident: e_1_3_2_142_2
  doi: 10.1016/j.vaccine.2011.06.068
– ident: e_1_3_2_152_2
  doi: 10.1093/cid/cis327
– ident: e_1_3_2_176_2
  doi: 10.1002/eji.200324257
– ident: e_1_3_2_191_2
  doi: 10.1093/cid/cir121
– reference: 6190093 - Nature. 1983 Jun 23-29;303(5919):706-9
– reference: 6198430 - J Exp Med. 1984 Feb 1;159(2):365-77
– reference: 21749769 - Emerg Infect Dis. 2011 Jun;17(6):1056-9
– reference: 15668219 - N Engl J Med. 2005 Jan 27;352(4):333-40
– reference: 17337102 - Vaccine. 2007 May 10;25(19):3871-8
– reference: 20689752 - MBio. 2010 May 18;1(1):null
– reference: 21460314 - Clin Infect Dis. 2011 Apr 15;52(8):1003-9
– reference: 19450640 - Vaccine. 2009 Dec 9;27(52):7451-8
– reference: 19587040 - J Virol. 2009 Sep;83(18):9296-303
– reference: 22351935 - J Immunol. 2012 Apr 1;188(7):3088-98
– reference: 22078723 - Lancet. 2011 Dec 3;378(9807):1917-30
– reference: 17475660 - J Virol. 2007 Jul;81(13):7111-23
– reference: 21464195 - Pediatrics. 2011 May;127(5):e1161-8
– reference: 1993950 - J Pediatr. 1991 Feb;118(2):235-8
– reference: 21624416 - Vaccine. 2011 Jul 18;29(32):5145-52
– reference: 15525714 - N Engl J Med. 2004 Nov 25;351(22):2295-301
– reference: 22718815 - J Virol. 2012 Sep;86(17):9233-43
– reference: 22738893 - Lancet Infect Dis. 2012 Sep;12(9):687-95
– reference: 20389023 - J Clin Invest. 2010 May;120(5):1663-73
– reference: 18230677 - Am J Epidemiol. 2008 Apr 1;167(7):775-85
– reference: 21481325 - Vaccine. 2011 May 23;29(23):3951-61
– reference: 20798667 - MMWR Morb Mortal Wkly Rep. 2010 Aug 27;59(33):1057-62
– reference: 6602294 - N Engl J Med. 1983 Jul 7;309(1):13-7
– reference: 20369059 - Clin Dev Immunol. 2010;2010:517198
– reference: 22265860 - Vaccine. 2012 Feb 27;30(10):1759-66
– reference: 6040602 - Nature. 1967 Feb 11;213(5076):612-4
– reference: 22678831 - Adv Ther. 2012 Jun;29(6):562-77
– reference: 302303 - J Exp Med. 1977 Sep 1;146(3):673-89
– reference: 22371588 - Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4269-74
– reference: 21220454 - J Exp Med. 2011 Jan 17;208(1):181-93
– reference: 16940524 - J Virol. 2006 Sep;80(18):9134-43
– reference: 22895385 - MMWR Morb Mortal Wkly Rep. 2012 Aug 17;61(32):613-8
– reference: 8578816 - Vaccine. 1995;13(15):1399-402
– reference: 15100298 - J Immunol. 2004 May 1;172(9):5553-60
– reference: 606797 - J Infect Dis. 1977 Dec;136 Suppl:S722-30
– reference: 21147034 - Trends Immunol. 2011 Jan;32(1):34-41
– reference: 19027046 - Vaccine. 2009 Jan 29;27(5):786-91
– reference: 20117262 - Vaccine. 2010 Mar 16;28(13):2565-72
– reference: 836542 - N Engl J Med. 1977 Mar 10;296(10):567-8
– reference: 21715575 - Clin Vaccine Immunol. 2011 Aug;18(8):1358-64
– reference: 320661 - Science. 1977 Mar 4;195(4281):834-47
– reference: 21865387 - J Virol. 2011 Nov;85(21):11048-57
– reference: 11257414 - Vaccine. 2001 Mar 21;19(17-19):2716-21
– reference: 19079604 - PLoS One. 2008;3(12):e3942
– reference: 18768983 - J Virol. 2008 Nov;82(21):10502-9
– reference: 22575166 - Vaccine. 2012 Jun 29;30(31):4655-60
– reference: 21253784 - Curr Top Microbiol Immunol. 2012;351:113-38
– reference: 19892174 - Methods Enzymol. 2009;463:191-222
– reference: 19197383 - PLoS One. 2009;4(2):e4384
– reference: 9927581 - Virology. 1999 Feb 1;254(1):138-46
– reference: 10725408 - Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4309-14
– reference: 22192847 - Vaccine. 2012 Feb 8;30(7):1388-96
– reference: 20394719 - Vaccine. 2010 May 21;28(23):3929-35
– reference: 19368793 - Vaccine. 2009 Apr 21;27(18):2506-12
– reference: 22956656 - Clin Vaccine Immunol. 2012 Nov;19(11):1792-7
– reference: 19508159 - J Infect Dis. 2009 Jul 15;200(2):172-80
– reference: 19768415 - Curr Top Microbiol Immunol. 2009;333:369-93
– reference: 21723354 - Vaccine. 2011 Aug 11;29(35):5911-8
– reference: 12686093 - Vaccine. 2003 May 1;21(16):1776-9
– reference: 35954 - Acta Virol. 1979 Jan;23(1):1-8
– reference: 21995388 - N Engl J Med. 2011 Oct 13;365(15):1406-16
– reference: 19840663 - Vaccine. 2009 Oct 23;27(45):6296-9
– reference: 10430945 - Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9345-50
– reference: 22424235 - Cell. 2012 Mar 16;148(6):1284-92
– reference: 21277410 - Vaccine. 2011 Mar 9;29(12):2272-8
– reference: 16556800 - Science. 2006 Apr 21;312(5772):399
– reference: 20195520 - PLoS Pathog. 2010 Feb;6(2):e1000796
– reference: 9548456 - J Immunol. 1997 Dec 1;159(11):5197-200
– reference: 19716456 - Vaccine. 2009 Nov 5;27(47):6589-94
– reference: 17766014 - Vaccine. 2007 Oct 10;25(41):7065-74
– reference: 18294741 - Vaccine. 2008 Mar 17;26(12):1525-9
– reference: 20713260 - Vaccine. 2010 Sep 7;28 Suppl 4:D45-53
– reference: 22508490 - Mol Ther. 2012 Jul;20(7):1472-80
– reference: 21816199 - Vaccine. 2011 Oct 13;29(44):7826-34
– reference: 10801978 - Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13
– reference: 12690201 - Science. 2003 Apr 11;300(5617):337-9
– reference: 335000 - J Infect Dis. 1977 Nov;136(5):623-32
– reference: 18947524 - Euro Surveill. 2008 Oct 23;13(43). pii: 19017
– reference: 19410623 - Vaccine. 2009 Jun 24;27(31):4099-103
– reference: 18366521 - Respirology. 2008 Mar;13 Suppl 1:S10-3
– reference: 15367555 - JAMA. 2004 Sep 15;292(11):1333-40
– reference: 18652550 - J Infect Dis. 2008 Sep 1;198(5):650-8
– reference: 10073729 - Vaccine. 1999 Feb 5;17(5):497-507
– reference: 15064027 - Lancet. 2004 Apr 3;363(9415):1099-103
– reference: 6724694 - Infect Immun. 1984 Jun;44(3):730-3
– reference: 22228256 - Adv Ther. 2012 Jan;29(1):41-52
– reference: 19095024 - Vaccine. 2009 Feb 11;27(7):1101-10
– reference: 2222834 - Adv Biotechnol Processes. 1990;14:203-42
– reference: 20615991 - Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13701-6
– reference: 23077318 - J Virol. 2013 Jan;87(1):363-71
– reference: 21596084 - Vaccine. 2011 Jul 12;29(31):4897-902
– reference: 6332992 - Nature. 1984 Oct 11-17;311(5986):578-9
– reference: 21251008 - Ann N Y Acad Sci. 2011 Jan;1217:178-90
– reference: 16267134 - Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16825-9
– reference: 23159882 - Nat Biotechnol. 2012 Dec;30(12):1210-6
– reference: 19540952 - Vaccine. 2009 Aug 6;27(36):4953-60
– reference: 15709000 - J Virol. 2005 Mar;79(5):2814-22
– reference: 959116 - Postgrad Med J. 1976 Jun;52(608):360-7
– reference: 16714186 - Lancet. 2006 May 20;367(9523):1657-64
– reference: 21737702 - Science. 2011 Aug 12;333(6044):843-50
– reference: 16050515 - Epidemiol Infect. 2005 Aug;133(4):687-93
– reference: 8257115 - Annu Rev Microbiol. 1993;47:765-90
– reference: 21169548 - J Immunol. 2011 Jan 15;186(2):1022-31
– reference: 20865762 - Ann Neurol. 2010 Nov;68(5):762-6
– reference: 18802496 - J Clin Invest. 2008 Oct;118(10):3478-90
– reference: 20542248 - Cell Host Microbe. 2010 Jun 25;7(6):440-51
– reference: 19416838 - Proc Natl Acad Sci U S A. 2009 May 12;106(19):7962-7
– reference: 21968298 - Virus Res. 2011 Dec;162(1-2):31-8
– reference: 19234466 - Nat Struct Mol Biol. 2009 Mar;16(3):265-73
– reference: 20689501 - MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1-62
– reference: 16860659 - Adv Cancer Res. 2006;95:203-47
– reference: 16227302 - J Virol. 2005 Nov;79(21):13811-6
– reference: 11591118 - Cell Immunol. 2001 Aug 1;211(2):143-53
– reference: 1258359 - Virology. 1976 Feb;69(2):511-22
– reference: 13094502 - Bull World Health Organ. 1953;8(5-6):725-41
– reference: 12690202 - Science. 2003 Apr 11;300(5617):339-42
– reference: 22330956 - Hum Vaccin Immunother. 2012 Mar;8(3):411-4
– reference: 10773346 - Hum Immunol. 2000 May;61(5):438-52
– reference: 22537989 - Vaccine. 2012 Jul 6;30(32):4884-91
– reference: 15620476 - Vaccine. 2005 Jan 11;23(8):1029-36
– reference: 21975270 - Lancet Infect Dis. 2011 Dec;11(12):916-24
– reference: 10578119 - Rev Med Virol. 1999 Oct-Dec;9(4):237-44
– reference: 15100303 - J Immunol. 2004 May 1;172(9):5598-605
– reference: 21798894 - Science. 2011 Aug 12;333(6044):850-6
– reference: 20071564 - J Virol. 2010 Apr;84(7):3312-9
– reference: 19776407 - N Engl J Med. 2009 Sep 24;361(13):1260-7
– reference: 10358753 - Annu Rev Immunol. 1999;17:51-88
– reference: 19171569 - Pediatrics. 2009 Feb;123(2):e186-92
– reference: 22723413 - Science. 2012 Jun 22;336(6088):1534-41
– reference: 22326774 - Vaccine. 2012 Mar 28;30(15):2535-42
– reference: 19122146 - Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):540-5
– reference: 9302747 - Vaccine. 1997 Aug-Sep;15(12-13):1372-8
– reference: 11390617 - J Virol. 2001 Jul;75(13):6154-65
– reference: 1068196 - J Hyg (Lond). 1976 Oct;77(2):173-80
– reference: 15297047 - Vaccine. 2004 Aug 13;22(23-24):2993-3003
– reference: 20617311 - Appl Microbiol Biotechnol. 2010 Sep;88(2):461-75
– reference: 18842709 - J Virol. 2008 Dec;82(24):12241-51
– reference: 5662705 - J Immunol. 1968 Jul;101(1):62-7
– reference: 22470453 - PLoS One. 2012;7(3):e33536
– reference: 18260764 - J Infect Dis. 2008 Mar 1;197(5):667-75
– reference: 19751689 - Vaccine. 2009 Nov 16;27(49):6959-65
– reference: 303150 - Cell Immunol. 1977 Oct;33(2):423-36
– reference: 17728025 - Vaccine. 2007 Oct 10;25(41):7017-30
– reference: 22441650 - Clin Infect Dis. 2012 Jul;55(1):19-25
– reference: 21751080 - Adv Ther. 2011 Aug;28(8):640-9
– reference: 22226861 - Vaccine. 2012 Mar 2;30(11):1993-8
– reference: 15525713 - N Engl J Med. 2004 Nov 25;351(22):2286-94
– reference: 16823947 - Vaccine. 2006 Jun 5;24(23):4897-4900
– reference: 19673652 - J Infect Dis. 2009 Sep 15;200(6):849-57
– reference: 16473124 - Lancet. 2006 Feb 11;367(9509):475-81
– reference: 14971045 - Eur J Immunol. 2004 Jan;34(1):194-9
– reference: 23228813 - Vaccine. 2013 Jan 21;31(5):770-6
– reference: 14505903 - Vaccine. 2003 Oct 1;21(27-30):4234-7
– reference: 21422814 - Hum Vaccin. 2011 May;7(5):539-48
– reference: 21963677 - Virus Res. 2011 Dec;162(1-2):19-30
– reference: 20004635 - Vaccine. 2010 Feb 3;28(5):1156-67
– reference: 6174976 - Proc Natl Acad Sci U S A. 1981 Dec;78(12):7639-43
– reference: 19673651 - J Infect Dis. 2009 Sep 15;200(6):841-8
– reference: 19745215 - N Engl J Med. 2009 Dec 17;361(25):2424-35
– reference: 21148512 - Clin Infect Dis. 2011 Jan 1;52(1):1-7
– reference: 20956293 - Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18979-84
– reference: 19368768 - Vaccine. 2009 Mar 18;27(13):1889-97
– reference: 20445182 - N Engl J Med. 2010 May 6;362(18):1708-19
– reference: 22275400 - J Infect Dis. 2012 Mar 1;205(5):697-9
– reference: 19849996 - Vaccine. 2009 Dec 9;27(52):7304-12
– reference: 20810680 - Clin Vaccine Immunol. 2010 Nov;17(11):1817-9
– reference: 22275399 - J Infect Dis. 2012 Mar 1;205(5):703-12
– reference: 3524050 - Vaccine. 1986 Jun;4(2):114-8
– reference: 11599686 - Eur J Epidemiol. 2001;17(2):135-40
– reference: 21245655 - Hum Vaccin. 2011 Jan-Feb;7 Suppl:29-40
– reference: 16143432 - Vaccine. 2005 Dec 30;23(50):5751-9
– reference: 1068195 - J Hyg (Lond). 1976 Oct;77(2):161-72
– reference: 21232649 - Vaccine. 2011 Mar 3;29(11):2010
– reference: 21968444 - Vaccine. 2011 Nov 8;29(48):8788-801
– reference: 22406460 - Vaccine. 2012 Nov 6;30(48):6946-54
– reference: 21835220 - Vaccine. 2011 Oct 13;29(44):7733-9
– reference: 2741346 - Virology. 1989 Jul;171(1):275-9
– reference: 22982990 - Nature. 2012 Sep 27;489(7417):526-32
– reference: 9060631 - J Virol. 1997 Apr;71(4):2772-8
– reference: 16494711 - Emerg Infect Dis. 2006 Jan;12(1):15-22
– reference: 22722205 - Nature. 2012 Jun 21;486(7403):420-8
– reference: 18413603 - Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):5986-91
– reference: 306072 - Nature. 1978 May 18;273(5659):238-9
– reference: 22500272 - Aging Dis. 2012 Feb;3(1):68-90
– reference: 20534862 - J Virol. 2010 Sep;84(17):8369-88
– reference: 22032844 - Lancet Infect Dis. 2012 Jan;12(1):36-44
– reference: 11919291 - Mol Biol Evol. 2002 Apr;19(4):501-9
– reference: 21242525 - J Immunol. 2011 Feb 15;186(4):2422-9
– reference: 16554799 - Nature. 2006 Mar 23;440(7083):435-6
– reference: 23474244 - Int J Cardiol. 2013 Sep 10;167(6):2397-403
– reference: 15541448 - Lancet. 2004 Nov 13-19;364(9447):1757-65
– reference: 21821086 - Vaccine. 2011 Oct 6;29(43):7559-71
– reference: 18627206 - Drugs. 2008;68(11):1483-91
– reference: 21237476 - Virology. 2011 Mar 15;411(2):229-36
– reference: 21029960 - Immunity. 2010 Oct 29;33(4):492-503
SSID ssj0014438
Score 2.5467317
SecondaryResourceType review_article
Snippet Classifications Services CMR Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit...
The challenges in successful vaccination against influenza using conventional approaches lie in their variable efficacy in different age populations, the...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
crossref
highwire
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 476
SubjectTerms Adjuvants, Immunologic
Animals
Applied microbiology
Biological and medical sciences
Birds
Fundamental and applied biological sciences. Psychology
Humans
Infectious diseases
Influenza Vaccines - administration & dosage
Influenza Vaccines - immunology
Influenza, Human - prevention & control
Medical sciences
Microbiology
Orthomyxoviridae Infections - prevention & control
Reviews
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - immunology
Title Traditional and New Influenza Vaccines
URI http://cmr.asm.org/content/26/3/476.abstract
https://www.ncbi.nlm.nih.gov/pubmed/23824369
https://www.proquest.com/docview/1398423912
https://pubmed.ncbi.nlm.nih.gov/PMC3719499
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbQEIgXBONXBkxBAl6qlMR2nOQRVaAxVCRYQXuzLo4jKtFsaruH7a_nHNupO4o0eImixI5lf-fL2b77jpDXGeOCA8sTnDuQcC1a1IN4p7KW5qxhGvrwsekXcfSdH5_mpz5DtosuWddjdbUzruR_UMVniKuJkv0HZIeP4gO8R3zxigjj9WYYL6GZu808swFunBU_2awjVzD6Acqcmq9C-3PiAyEX84CByVGSDgrauemeoAGenGzEx5zeXAbR-KPjcbhpYBI4FH7TwOmWiiVobFlFqK3uM9Si-LsuQ-Vow9mdELBA0_FCBD9NbhPa_amPqYkxmEy_jfuIkcQ3GNJeX_sdDU6C_fKElhJry762NNmkb1NcDxiF9vnr5riI8z5l-dArH-FAy3dh29u2h-eDNu6wsMKhb20qk11rjesus4ENMntA7rvFQ_zeSsJDckt3--SOTSd6uU_uTp2jxCPyNhCNGEUjRtGIB9GIvWg8JrOPH2aTo8SlxEgUmqrrpOEgIIOKp2XN6qLRlaJMF1ppcy7PWi2yJm2rKged1YoVwFQOOB9xOqKdqNgTsteddfoZiWsGBQdV8gzwNRMAUKVpIwxhX12mZURGfqykcnTxJmvJL7kLl4i8GUqfW5qUv5SL_LBLWC2kWiwlFZJJFKeIHG7hMHyIFnkmBK0i8soDI1EJmpMt6PTZxUriMqY0TJamgacWqE1tVlLsH9YutiAcChiC9e033fxnT7TOisxwNx3csHPPyb3NXHtB9tbLC_0STdZ1fdiL628FaZIs
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Traditional+and+New+Influenza+Vaccines&rft.jtitle=Clinical+microbiology+reviews&rft.au=Wong%2C+Sook-San&rft.au=Webby%2C+Richard+J.&rft.date=2013-07-01&rft.issn=0893-8512&rft.eissn=1098-6618&rft.volume=26&rft.issue=3&rft.spage=476&rft.epage=492&rft_id=info:doi/10.1128%2FCMR.00097-12&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_CMR_00097_12
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0893-8512&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0893-8512&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0893-8512&client=summon